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Association between Serotonin-Related Polymorphisms 
in 5HT2A, TPH1, TPH2 Genes and Bipolar Disorder  
in Korean Population
ObjectiveaaThe aim of the present study was to examine the association between serotonin-
related gene polymorphisms and bipolar disorder in the Korean population. In addition, we 
sought to explore the relationship between the clinical characteristics of bipolar patients and 
serotonin-related gene polymorphisms. 
MethodsaaInpatients with bipolar disorder (n=103) and control subjects (n=86) were geno-
typed for 5HT2A 1438A/G, tryptophan hydroxylase 1 (TPH1) 218 A/C, and TPH2 703G/T. 
We divided patients with bipolar disorder into two groups according to the presence of psycho-
tic symptoms. The severity of their symptoms was measured using the Young Mania Rating Sc-
ale (YMRS) and the Brief Psychiatric Rating Scale (BPRS).
ResultsaaThere were no significant differences in the genotype distributions or allelic frequ-
encies in the three serotonergic polymorphisms between patients with bipolar disorder and nor-
mal controls. There were significant differences in genotype distributions and allele frequ-
encies of the 5-HT2A -1438A/G polymorphism between the psychotic mania group and the 
non-psychotic mania group (genotype: χ2=7.50, p=0.024; allele: χ2=5.92, p=0.015). Howev-
er, after Bonferroni correction this signifact difference disappeared. We did not find significant 
differences in the genotype distributions or allelic frequencies in the TPH1 218 A/C and TPH2 
703G/T polymorphisms between the psychotic mania group and non-psychotic mania group.
ConclusionaaWe failed to found the statistically significant association between three poly-
morphisms and bipolar disorder. However, there was a trend towards association between 
5-HT2A -1438A/G polymorphism and psychotic symptom in bipolar disorder. Future research 
should seek to clarify this association.   Psychiatry Investig 2010;7:60-67
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Introduction
Bipolar disorder is relatively common psychiatric illness with a lifetime prevalence of 
0.5-1.0%.
1 The heritability of bipolar disorder is estimated to be as high as 85%,
2 and profound 
efforts have been put forth in an attempt to elucidate the genetics of the illness. Nevertheless, 
the susceptibility genes for bipolar disorder have proven elusive. This may be due to many 
genes of small effect sizes contributing to the risk of developing the disorder. 
Disturbance of the serotonergic system has been implicated in the etiology of bipolar disor-
der. A number of studies of candidate genes involved in serotonin metabolism and serotoner-
gic transmission have been investigated. 
The serotonin 2A receptor (5-HT2A) gene is located on chromosome 13q14-q21. It consists 
of three exons and two introns, spanning over 63 kb. The 1438A/G polymorphism is locat-
ed on the promoter region of 5-HTR2A, and the 102T/C polymorphism is located on axon 
1. The -1438A/G single nucleotide polymorphism (SNP) is in strong linkage disequilibrium 
with 102T/C SNP.
3 A 1438A/G polymorphism has the potential to modulate 5-HT2A pro-
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moter activity
4 and may be associated with the pathogenesis 
of bipolar disorder.
Several studies have examined the association between 
5-HT2A receptor genes and bipolar disorder, though the re-
sults have proven inconsistent. A previous study of the Korean 
population suggested that the 1438A/G polymorphism of the 
5-HT2A receptor gene promoter may be associated with the 
development of bipolar disorder.
5 However, other studies have 
reported that the 5-HT2A receptor 1438A/G is not associated 
with bipolar disorder.
6,7
Patients who are heterozygous for T and C alleles at 102 de-
velop bipolar disorder earlier than patients who are homozy-
gous for the C allele.
8 We could therefore hypothesize that if 
the 1438A/G polymorphism alters 5-HT2A promoter activity, 
it may also alter the mean age of onset.
Tryptophan hydroxylase (TPH) catalyzes the biopterin-de-
pendent monooxygenation of tryptophan to 5-hydroxytryp-
tophan, which is subsequently decarboxylated to form sero-
tonin.
9 TPH is a rate-limiting enzyme involved in the biosyn-
thesis of serotonin. Two TPH isoforms have been identified. 
The TPH2 gene is predominantly expressed in the brainstem, 
especially in the raphe nuclei neuron in which serotonergic 
neurons are the main neuronal components in a rodent model.
10 
The TPH1 gene is expressed predominantly in the pineal gland 
and, to some extent, in the peripheral tissues (duodenum, kid-
neys, or lungs).
11
The TPH1 gene is located on chromosome 11p15.3-p14. The 
218A/C SNP is reported in intron 7 of the TPH1 gene. The 
TPH1 gene has been implicated in several psychiatric condi-
tions, such as bipolar disorder,
12 suicidal behavior,
13 alcohol-
ism,
13 and aggression-related traits.
14 However, such associa-
tions were not replicated in other studies involving suicidal 
behavior
15,16 and bipolar disorder.
17 In a recent meta-analysis, 
the homozygous recessive genotype of the TPH1 A218C po-
lymorphism was reported to increase the risk of bipolar dis-
order but not of major depressive disorder.
18 
The TPH2 gene is located on chromosome 12q21.1. In mice 
brain stems, the expression of TPH1 appears to be 150 times 
lower than TPH2,
19 suggesting that TPH2 may play a much 
more important role in serotonin synthesis in the brain than 
TPH1. Consequently, many studies have examined the poten-
tial role of TPH2 in the development of depression, suicide,
20,21 
and bipolar disorder.
21,22 In a postmortem study, higher levels 
of TPH2 expression were found in the dorsolateral prefrontal 
cortices of patients with bipolar disorder when compared to 
control subjects.
23
In the present work, we tested the hypothesis of an involve-
ment of the 5-HT2A, TPH1, and TPH2 genes in the develop-
ment of bipolar disorder. In addition, we assessed the modifi-
er role of these genes in the clinical characteristics of bipolar 
disorder (e.g., presence of psychotic features, age of onset, 
and number of episodes). 
Methods
Subjects
A total of 103 bipolar patients were recruited from Korea 
University’s Ansan Hospital. All subjects were recruited dur-
ing admission. All patients with bipolar disorder met the DSM-
IV criteria
24 for bipolar I disorder. Each patient was assessed 
by trained psychiatrists using a Structured Clinical Interview 
for DSM-IV Axis I Disorders (SCID-I)25 on the first day of 
their admission. In the case that patient couldn’t cooperate with 
the interview because of rapid tranquilization we assessed the 
patient next day or at the latest within 3 days after admission. 
We excluded subjects with Axis I or II psychiatric comorbid-
ities according to the DSM-IV, such as schizophrenia, alcohol 
abuse, substance abuse, or personality disorders. We also ex-
cluded subjects with significant organic brain disease or clini-
cally significant somatic disease. We also collected data such 
as age of onset, duration of illness, number of illness episodes 
using medical records and information from relatives because 
patients in acute manic state could not provide reliable infor-
mations on the first day of their admission. The normal con-
trol group consisted of healthy individuals who visited Korea 
University’s Ansan Hospital for regular health screening and 
volunteered to participate in this study. Participants were ex-
cluded if they had a personal or familial psychiatric history, 
had been diagnosed with a psychiatric illness, or had taken any 
kind of psychotropic medicines. A final total of 86 subjects 
were recruited. Written informed consent was obtained from 
all subjects. 
We assessed the severity of manic symptoms using the Young 
Mania Rating Scale (YMRS)26; the severity of psychotic symp-
toms were assessed using the Brief Psychiatric Rating Scale 
(BPRS).
27 The YMRS and BPRS were administered on the first 
day after admission. We acquired data on the clinical variables, 
such as number of episodes and duration of illness. Each case of 
bipolar disorder was categorized into one of two groups accord-
ing to the presence of psychotic features. Psychotic features in-
cluded grandiose delusions, auditory hallucinations, delusions 
of persecution, and delusions of reference. Patients were catego-
rized in the psychotic mania group if they had any of the psy-
chotic symptoms mentioned above during the index episode. 
  
Genotyping 
Deoxyribonucleic acid (DNA) was extracted from plasma 
leukocytes using the Wizard Genomic DNA Purification Kit 
(Promega, USA). In order to genotype the 1438A/G SNP in 
the 5-HTR2A gene, a polymerase chain reaction (PCR) was 
performed with the forward primer 5’-CTGGGTGGCATA-
TTTCTGCT-3’ (-1610 to -1591) and the reverse primer 5’-AC-
CAAGGGACTCCTGGTTTC-3’ (-1107 to -1088). 
The amplification mixture contained 1 μL of 100 ng/μL 
DNA, 5 μL of 10× PCR buffer, 4 μL of 2.5 mM Ex dNTP mix-62  Psychiatry Investig 2010;7:60-67
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ture, 2 μL primer, 37.75 μL distilled water, and 0.25 μL Taq 
polymerase (TaKaRa, Japan). Samples were amplified using 
a Thermocycler (GeneAmp PCR system 2700, Applied Bio-
systems, Foster City, CA, USA) for 35 cycles. The thermal cy-
cling conditions were: 94℃ for 5 min, followed by 35 cycles 
of 94℃ for 30s, 62℃ for 30s, 72℃ for 30s, and ending with 
72℃ for 5 min (GenoAmp PCR system 2700, Applied Bio-
systems). The amplified DNA was digested with the restric-
tion enzyme MspI (Promega, USA), which cuts at the 1438G 
sites. The product was electrophoresed on 3% agarose gels and 
stained with ethidium bromide. Homozygous genotypes were 
identified by the presence of a single 513-bp band (A/A), or 
bands of 313- and 182-bp (G/G). The heterozygous genotype 
(A/G) displayed all three band sizes. In order to genotype the 
218A/C SNP in the TPH gene, the reaction mixture consisted 
of 100 ng of DNA, 2.5 mM Ex dNTP mixture, 5 unit Ex Tag 
polymerase, 10× Ex Tag buffer (all TaKaRa, Japan), and 10 
pmoL of each primer (forward primer: 5’-CGTCCTGTGGC-
TGGTTACTT-3’, reverse primer: 5’-CACGCTGCAGTGC-
TTAACAT-3’). 
The thermal cycling conditions were: 94℃ for 5 min, fol-
lowed by 35 cycles of 94℃ for 30s, 56℃ for 30s, 72℃ for 
30s, and ending with 72℃ for 5 min (GenoAmp PCR system 
2700, Applied Biosystems). The product size was 881-bp. 
After the PCR and digestion by NheI enzyme for 2 h at 37℃ , 
the digested products were analyzed on 2% agarose gel. The 
TPH C allele was cleaved into fragments of 337- and 544-bp, 
while the A allele was uncut.
In order to genotype the 703G/T SNP in the TPH2 gene, the 
reaction mixture consisted of 100 ng of DNA, 2.5 mM Ex 
dNTP mixture, 5 unit Ex Tag polymerase, 10× Ex Tag buffer 
(all TaKaRa, Japan), and 10 pmoL of each primer (forward pri-
mer: 5’-TTTTATGAAAGCCATTACACAT -3’, reverse prim-
er: 5’-TTCCACTCTTCCAGTTATTTTA-3’). The thermal 
cycling conditions were: 95℃ for 5 min, followed by 36 cy-
cles of 95℃ for 45s, 51.9℃ for 45s, 72℃ for 45s, and end-
ing with 72℃ for 3 min to maximize the extension (GenoAmp 
PCR system 2700, Applied Biosystems). The product size 
was 881-bp. After the PCR and digestion by NheI enzyme 
for 4 h at 37℃ , the digested products dyed with ethidium bro-
mide were analyzed on 3% agarose gel. The TPH G allele was 
cleaved into fragments of 55- and 149-bp, while the T allele 
was uncut.
Statistical analyses
The presence of Hardy-Weinberg equilibrium was tested 
by a χ2-test for goodness of fit. Differences in clinical variables 
(age, age of onset, number of episodes, years of education, and 
duration of illness) were assessed using t-tests. Differences 
in genotype and allele frequencies between the bipolar disor-
der group and the normal control group were evaluated using 
a χ2-test. In addition, we divided the bipolar disorder group 
into two groups according to presence of psychotic symptoms. 
We then used a χ2-test to compare the frequencies of geno-
type and allele of each subgroup with those of the normal 
control group. The possibility that the genotypes of the three 
candidate genes influenced severity of symptom (YMRS, BP-
RS) and longitudinal course of illness (age of onset, number 
of episodes) was assessed using one-way analysis of variance 
(ANOVA). The analysis was performed using Statistical Pack-
age for the Social Sciences version 12.0. To consider the mul-
tiple comparisons, a Bonferroni correction was applied. Thus 
the p value for reaching significance is 0.0056 (0.05/9). Post-
hoc power analysis using QUANTO 1.2.3 program (http://hy-
dra.usc.edu/gxe) showed that for G allele frequency of 5-HT2A 
-1438A/G of 0.049, the power was 0.311 [case=103, control= 
86; α=0.05; odds ratio (OR) of A/G and G/G=1.685; disease 
frequency=0.01].
Table 1. Symptom and characteristic comparison between controls and patients with bipolar disorder
Characteristic Comparison subjects
(N=86)
Patients with bipolar disorder
Analysis All patients
(N=103)
Psychotic mania 
patients (N=78)
Non-psychotic mania 
patients (N=25)
Mean±SD Mean±SD Mean±SD Mean±SD t p
Age at interview 31.2±9.7 33.7±10.6 33.6±10.2 34.0±11.9 0.14 0.89†
Age of onset 29.7±10.7 29.7±10.6 30.0±11.4 0.09 0.93‡ 
No. of episodes 1.99±1.91 1.94±2.07 2.13±1.36 0.40 0.69‡ 
Years of education 12.2±2.60 12.2±2.70 12.2±2.50 0.02 0.99‡ 
Duration of illness 49.6±65.2 51.0±68.7 42.4±44.1 0.40 0.69‡ 
Baseline YMRS 33.5±9.50 34.0±9.00 31.8±11.0 0.89 0.37‡
Baseline BPRS 21.2±8.70 22.6±8.10 16.6±9.20 2.82 0.006*‡
N % N % N % N % χ2 (df=2) p 
Female (sex) 35 40.7 57 55.3 44 56.4 13 52.0 4.17 0.12†
*p<0.05, †t-test between comparison subjects and patients with bipolar disorder. ‡t-test between patients with psychotic features and 
patients without psychotic features. SD: standard deviation, YMRS: Young Mania Rating Scale, BPRS: Brief Psychiatric Rating ScaleKY Choi et al.
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Results
Characteristics of the subjects
There were no differences in age or gender distribution be-
tween the bipolar patient group and the control group (Table 
1). There were no significant difference in age of onset, num-
ber of episodes, years of education, duration of illness, or base-
line YMRS score between the psychotic mania group and the 
non-psychotic mania group. However, the psychotic mania 
group had significantly higher BPRS scores than the non-
psychotic mania group (psychotic mania group: 22.6±8.7; 
non-psychotic mania: 16.6±9.2).
Genotype and allele frequencies of the three
polymorphisms in the control and bipolar 
disorder groups
The distribution of the 5-HTR2A 1438A/G, TPH 218A/C, 
and TPH2 703G/T polymorphisms in bipolar patients and 
controls were in agreement with Hardy-Weinberg equilibri-
um. There were no significant statistical differences in the geno-
type distributions or allele frequencies of the three tested po-
lymorphisms between the bipolar disorder group and the con-
trol group (Table 2). 
Genotype and allele frequencies of the three 
polymorphisms in the psychotic mania group 
and non-psychotic mania group
Post-hoc tests did reveal differences in genotype distribu-
tions and allele frequencies of 5-HT2A -1438A/G polymor-
phism between the psychotic mania group and the non-psy-
chotic mania group (Table 3). Moreover, there was a signifi-
cant difference when we categorized genotype into two groups 
according to the presence of allele G (AA vs. AG+GG, χ2= 
6.83, p=0.009)(Table 4). However, after applying the Bon-
Table 2. Genotype and allele frequencies in controls and patients with bipolar disorder
5-HT2A receptor gene
promoter -1438A/G
Genotype Analysis Allele Analysis
A/A A/G G/G χ2 (df=2) p A G χ2 (df=1) p
Comparison subjects (N=86) 27 38 21 3.01 0.223 92 80 0.75 0.388
31.4% 44.2% 24.4% 53.5% 46.5%
Patients with bipolar disorder 22 57 24 101 105
All patients (N=103) 21.3% 55.3% 23.3% 49.0% 51.0%
    Patients with psychotic  12 45 21 7.50 0.024* 69 87 5.92 0.015*
        Features (N=78) 15.4% 57.7% 26.9% 44.2% 55.8%
    Patients without psychotic  10 12 3 32 18
        Features (N=25) 40.0% 48.0% 12.0% 64.0% 36.0%
TPH1 gene promoter -218A/C A/A A/C C/C χ2 (df=2) p A C χ2 (df=1) p
Comparison subjects (N=86) 28 39 19 0.187 0.911 95 77 0.203 0.652
32.6% 45.3% 22.1% 55.2% 44.8%
Patients with bipolar disorder 31 47 25 109 97
All patients (N=103) 30.1% 45.6% 24.3% 52.9% 47.1%
    Patients with psychotic  26 36 16 3.01 0.222 88 68 3.16 0.076
        Features (N=78) 33.3% 46.2% 20.5% 56.4% 43.6%
    Patients without Psychotic  5 11 9 21 29
        Features (N=25) 20.0% 44.0% 36.0% 42.0% 48.0%
TPH2 gene promoter -703G/T G/G G/T T/T χ2 (df=2) p G T χ2 (df=1) p
Comparison subjects (N=86) 17 40 29 1.48 0.477 74 98 0.782 0.376
8.1% 46.5% 33.7% 43.0% 57.0%
Patients with bipolar disorder 28 42 33 98 108
All patients (N=103) 27.2% 40.8% 30.0% 47.6% 52.4%
    Patients with psychotic  22 31 25 0.207 0.902 75 81 0.065 0.798
        Features (N=78) 28.2% 39.7% 32.1% 48.1% 51.9%
    Patients without psychotic 6 11 8 23 27
        Features (N=25) 24.0% 44.0% 32.0% 46.0% 54.0%
*p<0.05, after Bonferroni correction significance dissapeared. TPH: tryptophan hydroxylase64  Psychiatry Investig 2010;7:60-67
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ferroni correction, the difference in genotype distributions 
disappeared (α=0.0056). No differences in either genotype 
distribution or allele frequencies of TPH1 -218A/C and TPH2 
-703G/T between the psychotic mania group and the non-psy-
chotic mania group were observed. 
Comparison of the characteristics of bipolar 
disorder according to the three polymorphisms
Symptom severity differences among the genotypes were 
also compared (Table 5). For the three gene polymorphisms, 
there were no significant differences in baseline BPRS, YMRS, 
age of onset, or number of episodes.
Discussion
We hypothesized that serotonin-related gene polymor-
phisms might affect the appearance of psychotic features in 
patients with bipolar disorder. Even though we failed to show 
a statistically significant result, the present study suggested 
that the 5-HT2A receptor gene promoter -1438A/G polymor-
phism might be associated with the presence of psychotic 
features in patients with bipolar disorder. Our result suggest-
ed that presence of the G allele could be associated with psy-
chotic feature in bipolar disorder.
There is some evidence that the 5-HT2A receptor affects 
the psychotic symptoms in psychiatric disorders. However, 
the relationship between the 5-HT2A receptor and affective 
disorders with psychotic features has not been investigated. In 
schizophrenia, activation of 5-HT2A receptors in the prefron-
tal cortex may contribute to psychotic symptoms by enhanc-
ing the excitation of the descending glutamate neuron, which 
excites the mesolimbic dopamine neuron it innervates down-
stream.
28,29 Both N-methyl-D-aspartate antagonist state (ket-
amine) and 5-HT2A agonist state (N,N-dimethyltryptamine, 
DMT) have been suggested as an appropriate model for psy-
choses. However, the two models have a difference in symp-
tomatology. In the DMT model, positive symptoms are almost 
more prominent than negative symptoms. In the ketamine 
model for schizophrenia, on the other hand, phenomena that 
resemble cognitive symptoms, negative symptoms, and cata-
tonic symptoms of schizophrenia were more prominent than 
they were in the DMT model for schizophrenia.
30 We could 
therefore argue that the 5-HT2A agonist model is more apt 
for explaining the psychotic features in bipolar disorder. In 
order to explain the results of our study, we could assume 
that 5-HT2A promoter -1438A/G polymorphism affected the 
promoter activity or expression of the 5-HT2A receptor during 
manic episodes. In detail, allele -G at 5-HT2A gene promoter 
Table 3. Genotype and allele frequencies in psychotic bipolar disorder group and non-psychotic bipolar disorder group, according to 
5-HT2A 1438A/G polymorphism
5-HT2A receptor gene 
promoter  -1438A/G 
Genotype Allele
A/A A/G G/G A G
Comparison subjects (N=86) 27 38 21 92 80
21.3% 55.3% 23.3% 49.0% 51.0%
Patients with psychotic  12 45 21 69 87
    Features (N=78) 15.4% 57.7% 26.9% 44.2% 55.8%
Patients without psychotic 10 12 3 32 18
    Features (N=25) 40.0% 48.0% 12.0% 64.0% 36.0%
χ2 p χ2 p
C vs. P+N 9.55 0.049 6.67 0.036
C vs. P 5.98 0.050 2.81 0.094
C vs. N 1.87 0.392 1.74 0.188
P vs. N 7.50  0.024* 5.92  0.015*
*p<0.05, but after Bonferroni correction significance dissapeared. C: comparison subjects, P: patients with psychotic features, N: Patients 
without psychotic features
Table 4. Odds ratio for having psychotic features in patients with bipolar disorder
5-HT2A -1438A/G  Psychotic mania Nonpsychotic mania OR 95% CI χ2 p
 A/A 12 10 1 NA
A/G 45 12 3.13 1.09-8.960     
G/G 21 03 5.83 1.34-25.43
A/G+G/G 66 15 3.66 1.33-10.10 6.83 0.009*†
*p<0.05,  but after Bonferroni correction significance dissapeared, †χ2 test between A/A and A/G+G/G. NA: not applicable, OR: odds 
ratio, CI: confidence intervalKY Choi et al.
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-1438 may have increased the expression of 5-HT2A recep-
tors during manic episodes, thereby predisposing the 5-HT2A 
agonist state that produced the psychotic features. However, 
previous studies investigating the promoter activity of the 
5-HT2A -1438A/G polymorphism did not support this hypoth-
esis. Spurlock et al.
31 reported that there was no functional dif-
ference between allele A and allele G at 1438 locus in promot-
er activity. Yet in 2002, Myers et al.
32 demonstrated that in 
vitro assays showed neither A- nor G-allele of -1438 locus 
had significant effects on promoter activity when expressed 
with the major alleles at 1420C/T and -783A/G. However, 
promoter activity was decreased significantly when minor al-
lele G at 783 was expressed with G- allele at -1438. 
Another possible explanation is that the decreased activity 
of the 5-HT2A receptor, due to the polymorphism of the 
5-HT2A receptor gene, affects the 5HT2A-dopamine inter-
action to decrease the ability to stabilize the dopamine activ-
ity. Activation of the 5-HT2A receptor decreases the activity 
of dopaminergic neurons in the ventral tegmental area via 
gamma-aminobutyric acid interneurons.
33 The psychotic man-
ic state is supposed to be a hyperdopaminergic state. If the 
polymorphism in the 5-HT2A gene decreased the activity of 
5-HT2A, it would become the vulnerable gene for psychosis. 
We simultaneously investigated the association between 
three serotonin-related gene polymorphisms and bipolar dis-
order. To our knowledge, this is the first association study 
between TPH2 -703G/T polymorphisms and bipolar disorder 
in the Korean population. We found no association between 
TPH2 and bipolar disorder.
An example of gene-gene interaction was recently report-
ed when Lin et al.
34 demonstrated that TPH1 interacts with 
TPH2 to modify the risk for bipolar disorder. Those with the 
TPH2 at-risk TAG haplotype have the OR of 3.73 for devel-
oping bipolar disorder. Yet, if combined with TPH1 -346G al-
lele or TPH1 -346T, the odds ratio for bipolar disorder becomes 
4.81 or 1.68, respectively.
34 The presence of gene-gene inter-
action may explain why the results of association studies are 
inconsistent. In the future, efforts directed toward finding both 
gene-gene interactions and candidate genes for bipolar disor-
der are necessary.
A recent meta-analysis suggested that the homozygous gen-
otype of the TPH A218C polymorphism may increase the risk 
for bipolar disorder.
18 However, our study also suggested that 
the TPH1 A218C polymorphism was not associated with bipo-
lar disorder. 
In 2001, Oh et al.
35 investigated the association between the 
5-HT2A receptor gene promoter -1438A/G polymorphism 
and bipolar disorder in the Korean population. They suggest-
ed that the A allele is significantly more frequent in patients 
with bipolar disorder when compared to normal controls. In 
the present study, however, the 5-HTR2A 1438A/G polymor-
phisms were not associated with bipolar disorder. 
We hypothesized that the 5-HT2A -1438A/G polymorphism 
might alter the longitudinal course of the illness. Yet includ-
ing 5-HT2A, none of the three serotonin-related gene poly-
morphisms altered either mean age of onset or number of epi-
sodes. 
 It is worth noting the weaknesses of the present study. 
First, we interviewed the patients and their first-degree rela-
tives during their admissions and collected information about 
past history of affective episodes and the duration of illness. 
Consequently, we could not control recall bias. During manic 
Table 5. Comparison of clinical variables in bipolar disorder
5-HT2A receptor gene 
promoter -1438A/G 
Genotype ANOVA
A/A A/G G/G F p
Age of onset  26.4±8.80 31.2±11.6 29.3±9.90 1.517 0.225
No. of episode 2.0±1.9 2.3±2.1 1.4±1.5 1.564 0.215
Baseline YMRS 37.3±11.6 33.3±8.20 30.3±9.20 2.869 0.062
Baseline BPRS 22.4±10.9 21.6±8.10 19.1±7.80 0.826 0.442
TPH1 gene promoter-218A/C A/A A/C C/C F p
Age of onset  31.7±11.5 30.4±11.2 25.3±7.10 2.402 0.096
No. of episode 1.8±1.7 2.1±2.0 2.0±2.2 0.212 0.810
Baseline YMRS 34.0±11.0 33.5±7.90 32.7±10.6 0.110 0.896
Baseline BPRS 21.1±8.30 22.4±7.50 18.7±11.3 1.134 0.327
TPH2 gene promoter-703G/T G/G G/T T/T F p
Age of onset  29.1±10.5 30.9±12.0 28.6±9.20 0.447 0.641
No. of episode 1.6±1.8 2.0±1.8 2.3±2.2 0.827 0.440
Baseline YMRS 33.3±10.4 32.9±9.70 34.5±8.60 0.250 0.780
Baseline BPRS 23.9±10.1 20.7±8.40 19.9±7.90 1.305 0.277
YMRS: Young Mania Rating Scale, BPRS: Brief Psychiatric Rating Scale, ANOVA: analysis of variance66  Psychiatry Investig 2010;7:60-67
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episodes, patients and their families tended to remember pre-
vious manic episodes more than depressive episodes, possi-
bly causing the number of depressive episodes to be underes-
timated. Second, the relatively small sample size limited the 
power of investigating the possible associations between the 
above serotonin-related gene polymorphisms and bipolar dis-
order. 
In conclusion, we failed to found the statistically signifi-
cant association between three polymorphisms and bipolar 
disorder. However, there was a trend towards association be-
tween 5-HT2A -1438A/G polymorphism and psychotic symp-
tom in bipolar disorder. In future studies, large sample sizes 
should be used to confirm our results.
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